MODERNA COMPLETES CANADIAN MRNA MANUFACTURING FACILITY

eAwazMedicine

LAVAL – Moderna has completed construction of its state-of-the art mRNA manufacturing facility in Laval, Quebec. The facility is expected to be ready to manufacture respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals and certifications, ensuring all vaccines manufactured meet the strictest quality, safety and performance standards. The construction of this facility marks an important milestone in Moderna’s …

Alexion completes purchase for early-stage rare disease gene therapy portfolio from Pfizer

eAwazMedicine

 Boston – Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. …